The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Personalizing care in R/R follicular lymphoma: selecting patients for novel combination therapies
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses personalizing care in relapsed/refractory follicular lymphoma (R/R FL), particularly when selecting patients for novel chemotherapy-free bispecific triplet combinations. Dr Linton notes that fitness, age, and comorbidities must guide patient selection, and that these regimens should be reserved for higher-risk patients with early relapse. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
